8-K: Astrana Health Reports Record 2025 Results, Boosts Buyback

Astrana Health announced record revenue and adjusted EBITDA for 2025, alongside an increased share repurchase program, despite a delay in its 10-K filing due to an internal control weakness.

Summary

• Full-year 2025 total revenue reached $3,181.8 million, marking a 56% increase year-over-year and landing at the higher end of guidance.
• Full-year 2025 adjusted EBITDA was $205.4 million, up 21% from the previous year.
• Free cash flow for the full year 2025 stood at $104.5 million.
• Fourth quarter 2025 total revenue was $950.5 million, a 43% increase year-over-year.
• Fourth quarter 2025 adjusted EBITDA grew 50% year-over-year to $52.5 million.
• The company will file a Form 12b-25 to extend the deadline for its Annual Report on Form 10-K for the year ended December 31, 2025.
• A material weakness in internal control over financial reporting is anticipated, primarily related to acquisition and purchase accounting processes.
• The Board of Directors increased the maximum aggregate amount for the existing share repurchase program from $50 million to $100 million.
• During the fourth quarter of 2025, 633,844 shares were repurchased under the program.
• As of December 31, 2025, $35.9 million remained available under the share repurchase plan.
• Guidance for 2026 projects total revenue between $3,800 million and $4,100 million, and adjusted EBITDA between $250 million and $280 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a largely positive report, driven by strong financial performance and optimistic 2026 guidance, though tempered by the 10-K filing delay and material weakness disclosure.

Positives

• Record total revenue for 2025 of $3,181.8 million, up 56% year-over-year and at the higher end of guidance.
• Record adjusted EBITDA for 2025 of $205.4 million, representing a 21% increase year-over-year.
• Record free cash flow for 2025 of $104.5 million.
• Strong fourth quarter 2025 performance with total revenue up 43% to $950.5 million and adjusted EBITDA up 50% to $52.5 million.
• The share repurchase program authorization was increased from $50 million to $100 million, signaling management's confidence in the company's intrinsic value.
• Prospect Health integration is ahead of schedule, contributing to positive outlook.
• Anticipates robust 2026 growth with approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint.
• The identified material weakness does not reflect any material misstatement of financial results, nor does it require restatements of historical periods.
• Targeted investments are being made in the accounting organization to accelerate remediation of the material weakness.
• On track to receive 80% of revenue from fully capitated arrangements by the end of Q1 2026, indicating increased alignment and improved unit economics.
• Medical cost trends across both Prospect and legacy Astrana remained firmly within expectations for the year.
• Strong engagement in Annual Wellness Visits supports earlier intervention and improved care coordination.

Negatives

• The company will delay the filing of its Annual Report on Form 10-K for the year ended December 31, 2025.
• Anticipates reporting a material weakness in internal control over financial reporting, specifically related to acquisition and purchase accounting processes.

Risks

• The timing of filing the 2025 Form 10-K on or before the prescribed extension deadline.
• The expected material weakness in internal control over financial reporting, which may not be limited to acquisition and purchase accounting processes.
• The consistency of the financial statements in the 2025 Form 10-K with the financial information provided in the earnings release.
• The completion of all matters necessary to permit filing by the extension deadline.
• Actual results could differ materially from forward-looking statements due to various factors, including those identified in the company's most recent Form 10-K and other SEC filings.
• There is no assurance that forward-looking statements will be achieved.

Future Outlook

Astrana Health anticipates continued strong growth in 2026, projecting total revenue between $3,800 million and $4,100 million and Adjusted EBITDA between $250 million and $280 million. The company expects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint, driven by the successful integration of Prospect Health, which is ahead of schedule, and a continued shift towards full-risk contracts, aiming for 80% of revenue from fully capitated arrangements by Q1 2026. Targeted investments in the accounting organization are underway to remediate the identified material weakness.

Management Comments

• "Astrana delivered record revenue, adjusted EBITDA, and free cash flow in 2025, demonstrating the strength and predictability of our fully delegated, payer-agnostic care model and AI-enabled technology platform in a dynamic operating environment."
• "Our disciplined approach to risk, strong physician alignment, and technology-enabled clinical infrastructure drove consistent performance while creating measurable value for patients through improved outcomes, greater access, and lower total cost of care."
• "As we move through 2026, with Prospect Health integration ahead of schedule, we are confident in our ability to deliver on guidance that reflects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint."

Industry Context

StockSavvy.ai notes that Astrana Health's strong revenue and adjusted EBITDA growth, coupled with its strategic shift towards full-risk capitated arrangements and AI-enabled technology, positions it favorably within the evolving value-based care segment of the healthcare industry. The focus on physician alignment and improved patient outcomes aligns with broader industry trends emphasizing cost-efficiency and quality of care, differentiating it from traditional fee-for-service models. The successful integration of Prospect Health ahead of schedule suggests effective execution in a competitive M&A environment.

Comparison to Industry Standards

• Astrana Health's 56% year-over-year revenue growth in 2025 significantly outpaces the average growth rates of many established healthcare providers and managed care organizations, which typically range from single digits to low double digits.
• The projected 24% revenue growth and 29% adjusted EBITDA growth for 2026 at the midpoint are robust, indicating a strong competitive position and effective strategy execution compared to peers like Oak Street Health (acquired by CVS, but previously showed high growth) or ChenMed, which operate in similar value-based care models.
• The company's goal to achieve 80% of revenue from fully capitated arrangements by Q1 2026 demonstrates a deeper commitment to risk-bearing models than many traditional healthcare systems, aligning with the advanced value-based care strategies seen in leading integrated delivery networks.

Legal Proceedings

• A legal matter with a provider associated with CFC HP, which resulted in a $13.0 million cost for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong financial results, increased share repurchase program, and optimistic future guidance. Potential negative impact from the 10-K delay and material weakness, which could introduce uncertainty.
• Employees: Targeted investments in the accounting organization to remediate the material weakness may indicate increased workload or changes for accounting staff.
• Customers (Patients): Continued focus on improving patient outcomes, greater access, and lower total cost of care through the value-based care model.
• Providers: Strong physician alignment and continued shift towards full-risk contracts aim to better align incentives.
• Creditors: Compliance with debt and other agreements is a consideration for share repurchases.

Next Steps

• File the 2025 Form 10-K within the fifteen-day extension period provided under Rule 12b-25.
• Continue making targeted investments in the accounting organization to accelerate remediation of the material weakness.
• Continue to make repurchases under the share repurchase program following the filing of the 2025 Form 10-K.
• Host a conference call and webcast on March 2, 2026, to discuss Q4 and full-year 2025 financial results.

Key Dates

Recommendation

While Astrana Health delivered impressive financial results for 2025 and provided strong 2026 guidance, the simultaneous announcement of a material weakness in internal control over financial reporting and a delay in the 10-K filing introduces a notable element of uncertainty. The increased share repurchase program is a positive signal, but investors will likely await the resolution of the internal control issues and the filing of the complete 10-K before making significant new commitments. The stock is likely to experience volatility as the market digests both the strong performance and the governance concerns. A "hold" recommendation allows investors to monitor the remediation efforts and the full disclosure in the 10-K without reacting prematurely to either the positive financial news or the procedural setback.

Keywords

Astrana Health, ASTH, Healthcare Management, Financial Results, Earnings, Adjusted EBITDA, Revenue Growth, Share Repurchase, 10-K Filing Delay, Material Weakness, Internal Control, Value-Based Care, Acquisition Integration, Prospect Health